BioSpace News Archive

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that John Koconis, CEO of Timber, will present a corporate overview of the company, its development pipeline and near-term milestones at the Virtual Sum

Establishment Labs Holdings Inc., a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the Goldman Sachs 41st Annual Global Healthcare Conference Webcast, which is being held June 9-11, 2020.

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, Alimera’s President and Chief Executive Officer will give a corporate presentation at the June 2020 Virtual Summer Investor Summit taking place online from June 9- 12, 2020. The presentation will be held on Tuesday, June 9, 2020 at 3:55

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that patient enrollment in its Phase 3 clinical trial evaluating eprenetapopt with azacitidine for the treatment of front-line TP53 mutan

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, announced updated results from the Phase 1b portion of MISSION, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus with and without nephritis.

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in June:

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced that it intends to offer and sell up to $100 million of shares of its common stock in an underwritten public offering.

Clinical Ink, a global clinical trial technology company, has helped expedite the study of a treatment for cytokine storm, the immunological reaction associated with severe cases of COVID-19.

Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, has announced that it will undertake an overnight marketed public offering of units, comprised of Class A common shares and Class A common share purchase warrants.

CryoTreq adds to BVI’s rapidly expanding vitreoretinal portfolio including Vitreq® single-use instruments and Arcad® surgical fluids